Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
87.50%
Operating Margin
0.00%
Net Margin
-0.33%
Efficiency Metrics
Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
1.23%
Income Tax Rate
-13,500,000,000.0%
EPS
-1.2000000000
Balance Sheet Analysis
Current Ratio
0.26
Cash Ratio
0.14
Working Capital
$-31.27B
Debt to Equity
0.45
Debt to Assets
7.68%
Equity Ratio
17.19%
Cash Flow Analysis
Operating Cash Flow Ratio
7.41%
Free Cash Flow Ratio
6.94%
CapEx to Revenue
0.47%
Dividends Paid
$1.03B
Stock Buybacks
$335.00M
Total Shareholder Returns
$1.37B
Cash Position Change
-1.90%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 3.41%
Detailed Growth Metrics
Core Performance
Revenue
11.05%
Net Income
86.22%
EPS
76.14%
Operating Income
100.00%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
-92.24%
Operating Cash Flow
-17.44%
Free Cash Flow
-15.74%
Balance Sheet Health
Assets
5.52%
Debt
-0.28%
Book Value per Share
4.98%
Inventory
0.00%
Shareholder Returns
Dividends per Share
3.41%
Shares Outstanding
-3.21%
Long Term Trends
3Y Revenue/Share
51.31%
5Y Revenue/Share
90.00%
3Y Dividend/Share
57.87%
5Y Dividend/Share
82.80%